Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Journal of the National Cancer Institute
|
January 9, 2026
Targeting common EGFR mutations in NSCLC-review of global phase III trials of third-generation inhibitors
Barbara Melosky, Rosalyn A Juergens, Quincy S C Chu, et al.
Clinical Lung Cancer
|
May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC
Marina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Current Oncology (Toronto, Ont.)
|
April 26, 2024
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence
Ruth Moulson, Jennifer Law, Adrian Sacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Current Oncology (Toronto, Ont.)
|
July 28, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Parneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
British Journal of Cancer
|
October 11, 2025
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS<sup>G12C</sup> NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
Joshua C Rosen, Pinjiang Cao, Nhu-An Pham, et al.
JTO Clinical and Research Reports
|
June 20, 2022
Automating Access to Real-World Evidence
Marie-Pier Gauthier, Jennifer H Law, Lisa W Le, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 15, 2025
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
Jamie Feng, Katrina Hueniken, Zhen Jason Fan, et al.
Therapeutic Advances in Medical Oncology
|
October 30, 2025
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
Maisam Makarem, Tuan Hoang, Mitchell J Elliott, et al.
Clinical Lung Cancer
|
September 17, 2021
Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre
Sabine Schmid, Luna Zhan, Kristen Dietrich, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Journal of the National Cancer Institute
|
January 9, 2026
Targeting common EGFR mutations in NSCLC-review of global phase III trials of third-generation inhibitors
Barbara Melosky, Rosalyn A Juergens, Quincy S C Chu, et al.
Clinical Lung Cancer
|
May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC
Marina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Current Oncology (Toronto, Ont.)
|
April 26, 2024
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence
Ruth Moulson, Jennifer Law, Adrian Sacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Current Oncology (Toronto, Ont.)
|
July 28, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Parneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
British Journal of Cancer
|
October 11, 2025
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS<sup>G12C</sup> NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
Joshua C Rosen, Pinjiang Cao, Nhu-An Pham, et al.
JTO Clinical and Research Reports
|
June 20, 2022
Automating Access to Real-World Evidence
Marie-Pier Gauthier, Jennifer H Law, Lisa W Le, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 15, 2025
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
Jamie Feng, Katrina Hueniken, Zhen Jason Fan, et al.
Therapeutic Advances in Medical Oncology
|
October 30, 2025
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
Maisam Makarem, Tuan Hoang, Mitchell J Elliott, et al.
Clinical Lung Cancer
|
September 17, 2021
Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre
Sabine Schmid, Luna Zhan, Kristen Dietrich, et al.
Page
of 6